MEAF6
Chromatin modification-related protein MEAF6
Also known as: C1orf149, CENP-28, Eaf6, EAF6_HUMAN, FLJ11730, NY-SAR-91
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9HAF1
- Gene
- MEAF6
- Ensembl
- ENSG00000163875
- Chromosome
- 1
- Canonical length
- 191 aa
- Protein class
- Disease related genes, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Nuclear bodies
OverviewNCBI Gene
This gene encodes a nuclear protein involved in transcriptional activation. The encoded protein may form a component of several different histone acetyltransferase complexes. There is a pseudogene for this gene on chromosome 2. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2012]
Canonical amino-acid sequenceUniProt
191 residues, UniProt reviewed canonical sequence.
>Q9HAF1|MEAF6
1 MAMHNKAAPP QIPDTRRELA ELVKRKQELA ETLANLERQI YAFEGSYLED TQMYGNIIRG
61 WDRYLTNQKN SNSKNDRRNR KFKEAERLFS KSSVTSAAAV SALAGVQDQL IEKREPGSGT
121 ESDTSPDFHN QENEPSQEDP EDLDGSVQGV KPQKAASSTS SGSHHSSHKK RKNKNRHRID
181 LKLNKKPRAD YLocalizationUniProt · AlphaFold · HPA
Whether an antibody against MEAF6 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.59
- Highest tissue expression
- 54 nTPM
Expression across tissuesHPA
Tissue
- prostate: 54 nTPM
- parathyroid gland: 49 nTPM
- thymus: 47 nTPM
- seminal vesicle: 42 nTPM
- hypothalamus: 41 nTPM
- ovary: 38 nTPM
Single-cell type
- oocytes: 327 nCPM
- prostatic glandular cells: 245 nCPM
- esophageal apical cells: 235 nCPM
- epididymal efferent duct ciliated cells: 207 nCPM
- differentiating spermatogonia: 199 nCPM
- suprabasal keratinocytes: 183 nCPM
Immune cell
- eosinophil: 124 nTPM
- total PBMC: 115 nTPM
- T-reg: 110 nTPM
- basophil: 109 nTPM
- memory B-cell: 103 nTPM
- naive B-cell: 103 nTPM
Brain region
- hypothalamus: 61 nTPM
- basal ganglia: 43 nTPM
- cerebral cortex: 43 nTPM
- midbrain: 43 nTPM
- pons: 42 nTPM
- white matter: 38 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.65
- gnomAD pLI
- 0.13
- gnomAD missense Z
- 2.23
- DepMap mean gene effect
- -0.4
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 7% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- chromatin remodeling
- positive regulation of DNA-templated transcription
- positive regulation of double-strand break repair via homologous recombination
- regulation of apoptotic process
- regulation of cell cycle
- regulation of cell growth
- regulation of developmental process
- regulation of DNA biosynthetic process
- regulation of DNA replication
- regulation of DNA-templated transcription
- regulation of double-strand break repair
- regulation of hemopoiesis
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Chromatin modification-related protein Eaf6
- Histone acetyltransferase subunit NuA4
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of MEAF6 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MEAF6 as an antibody target. Whether an autoantibody or antibody against MEAF6 could matter depends on whether native MEAF6 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MEAF6 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label MEAF6 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...